Preetham Jetty, MD
Cardiovascular Disease · Anderson, INNPI 1962469510
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,340 of the $59,162 with a category attached, or 83.4%. 40 manufacturers reported payments, led by Amarin Pharma, Inc. at 49.9% of the total. Reporting peaked in 2019 at $17,848 and has fallen 94.8% since, to $930 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $137.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$30K
- Esperion Therapeutics, Inc.$23K
- Pfizer$1K
- Novartis$969
- Boehringer Ingelheim$605
- AstraZeneca$507
- plus $3K from 34 others
Across 110 payments — averaging $3283.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$179K
- Kowa Research Institute, Inc.$70K
- Merck$42K
- Astrazeneca UK Limited$25K
- Pfizer$22K
- Esperion Therapeutics, Inc.$15K
- plus $8K from 1 others
What the payments were for
- Speaking & faculty fees$49,34083%
- Travel & lodging$1,3052%
- Food & beverage$8,45514%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,162 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,081 | $1,383,954 |
| EntrestoSacubitril/Valsartan | 264 | $373,061 |
| Repatha SureclickEvolocumab | 273 | $300,499 |
| XareltoRivaroxaban | 191 | $257,463 |
| VascepaIcosapent Ethyl | 236 | $219,301 |
| MounjaroTirzepatide | 73 | $103,389 |
| JardianceEmpagliflozin | 61 | $87,212 |
| Praluent PenAlirocumab | 44 | $51,355 |
| Icosapent Ethyl | 96 | $48,038 |
| BrilintaTicagrelor | 67 | $44,883 |
| NexlizetBempedoic Acid/Ezetimibe | 40 | $36,942 |
| OzempicSemaglutide | 17 | $28,230 |
| FarxigaDapagliflozin Propanediol | 21 | $25,550 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 97 | $24,066 |
| Ranolazine ErRanolazine | 128 | $19,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,178 | $1,383,9541,081 claims |
| NovartisEntresto | $969 | $373,061264 claims |
| Johnson & JohnsonXarelto | $434 | $257,463191 claims |
| Boehringer IngelheimJardiance | $605 | $87,21261 claims |
| AstraZenecaBrilinta, Farxiga | $507 | $70,43388 claims |
| Esperion Therapeutics, Inc.Nexlizet | $23,008 | $36,94240 claims |
| Novo NordiskOzempic | $245 | $28,23017 claims |
| Astellas Pharma US IncMyrbetriq | $74 | $10,31014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Anderson
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.